

Applicants: Nancy Carrasco et al.  
Serial No.: 09/519,959  
Filed: March 7, 2000  
page 2

Amendments to the Specification:

Please enter the Sequence Listing attached hereto as **Exhibit 1** (1 page), and also enclosed herein in computer readable form, as the Sequence Listing for the subject application.

Please amend the paragraph on page 16, lines 15-23, to read as follows:

The following peptides, corresponding to C-terminal sequences of human NIS protein, were synthesized by solid phase synthesis (Carrasco *et al.*, 1986) and used to generate polyclonal human anti-NIS antibodies (Abs): peptide P-857, KELEGAGSWTPCVGHD (SEQ ID NO:1), corresponding to residues 618-633, and peptide P-858, GHDGGGRDQQETNL (SEQ ID NO:2), corresponding to residues 631-643 of NIS, were used to generate Abs Ct-1 and Ct-2, respectively. The protocol described in Levy *et al.* (1997) was followed to generate and purify polyclonal antibodies. Peptide NEDLLFFLGQKELE (SEQ ID NO:3), corresponding to residues 598-621, was used to generate the site-directed monoclonal Ab, as described in Harlow and Lane (1988).